317 related articles for article (PubMed ID: 30080874)
1. The anticancer peptide RT53 induces immunogenic cell death.
Pasquereau-Kotula E; Habault J; Kroemer G; Poyet JL
PLoS One; 2018; 13(8):e0201220. PubMed ID: 30080874
[TBL] [Abstract][Full Text] [Related]
2. A Cell-Penetrating Peptide Targeting AAC-11 Specifically Induces Cancer Cells Death.
Jagot-Lacoussiere L; Kotula E; Villoutreix BO; Bruzzoni-Giovanelli H; Poyet JL
Cancer Res; 2016 Sep; 76(18):5479-90. PubMed ID: 27406828
[TBL] [Abstract][Full Text] [Related]
3. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.
Qin J; Kunda N; Qiao G; Calata JF; Pardiwala K; Prabhakar BS; Maker AV
Cell Death Dis; 2017 Feb; 8(2):e2584. PubMed ID: 28151483
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis.
Aftabizadeh M; Li YJ; Zhao Q; Zhang C; Ambaye N; Song J; Nagao T; Lahtz C; Fakih M; Ann DK; Yu H; Herrmann A
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491667
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53.
Habault J; Kaci A; Pasquereau-Kotula E; Fraser C; Chomienne C; Dombret H; Braun T; Pla M; Poyet JL
Oncoimmunology; 2020; 9(1):1728871. PubMed ID: 32158621
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor.
Troitskaya O; Varlamov M; Nushtaeva A; Richter V; Koval O
Molecules; 2020 Jun; 25(12):. PubMed ID: 32560527
[TBL] [Abstract][Full Text] [Related]
7. Chromomycin A
Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
Front Immunol; 2022; 13():941757. PubMed ID: 36439184
[TBL] [Abstract][Full Text] [Related]
8. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
Pramil E; Herbi Bastian L; Denèfle T; Nemati F; Xiao M; Lardé E; Maloum K; Roos-Weil D; Chapiro E; Le Garff-Tavernier M; Davi F; Decaudin D; Sarfati M; Nguyen-Khac F; Merle-Béral H; Karoyan P; Susin SA
Blood Adv; 2019 Oct; 3(20):2920-2933. PubMed ID: 31648314
[TBL] [Abstract][Full Text] [Related]
9. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
10. CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells.
Uscanga-Palomeque AC; Calvillo-Rodríguez KM; Gómez-Morales L; Lardé E; Denèfle T; Caballero-Hernández D; Merle-Béral H; Susin SA; Karoyan P; Martínez-Torres AC; Rodríguez-Padilla C
Cancer Sci; 2019 Jan; 110(1):256-268. PubMed ID: 30460757
[TBL] [Abstract][Full Text] [Related]
11. Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.
Nuccitelli R; McDaniel A; Anand S; Cha J; Mallon Z; Berridge JC; Uecker D
J Immunother Cancer; 2017; 5():32. PubMed ID: 28428881
[TBL] [Abstract][Full Text] [Related]
12. Anticancer metal drugs and immunogenic cell death.
Terenzi A; Pirker C; Keppler BK; Berger W
J Inorg Biochem; 2016 Dec; 165():71-79. PubMed ID: 27350082
[TBL] [Abstract][Full Text] [Related]
13. The oncolytic peptide LTX-315 triggers immunogenic cell death.
Zhou H; Forveille S; Sauvat A; Yamazaki T; Senovilla L; Ma Y; Liu P; Yang H; Bezu L; Müller K; Zitvogel L; Rekdal Ø; Kepp O; Kroemer G
Cell Death Dis; 2016 Mar; 7(3):e2134. PubMed ID: 26962684
[TBL] [Abstract][Full Text] [Related]
14. Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2-targeting moieties.
Han JH; Park J; Seo YW; Kim TH
FEBS Lett; 2018 Jan; 592(1):103-111. PubMed ID: 29193033
[TBL] [Abstract][Full Text] [Related]
15. Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models.
Humeau J; Lévesque S; Kroemer G; Pol JG
Methods Mol Biol; 2019; 1884():297-315. PubMed ID: 30465212
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
Vallespí MG; Pimentel G; Cabrales-Rico A; Garza J; Oliva B; Mendoza O; Gomez Y; Basaco T; Sánchez I; Calderón C; Rodriguez JC; Markelova MR; Fichtner I; Astrada S; Bollati-Fogolín M; Garay HE; Reyes O
J Pept Sci; 2014 Nov; 20(11):850-9. PubMed ID: 25044757
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin).
Tanaka M; Kataoka H; Yano S; Sawada T; Akashi H; Inoue M; Suzuki S; Inagaki Y; Hayashi N; Nishie H; Shimura T; Mizoshita T; Mori Y; Kubota E; Tanida S; Takahashi S; Joh T
Oncotarget; 2016 Jul; 7(30):47242-47251. PubMed ID: 27363018
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
[TBL] [Abstract][Full Text] [Related]
19. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
20. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
